_256_384.jpg)
News | June 19, 2024
Cipla EU to invest an additional € 3 million in Ethris
Cipla had earlier invested € 15 million in Ethris in 2022
Cipla had earlier invested € 15 million in Ethris in 2022
_256_384.jpg)
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Achira is engaged in development and commercialization of PoC medical test kits in India
The company has posted net profit of Rs. 4,121.55 crores for the Financial Year ended March 31, 2024
The company is committed to address this observation comprehensively within stipulated time
CHL is strengthening its play in the fast-growing beauty and personal care sector
_256_384.jpg)
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Mungara has over 25+ years of experience in the supply chain domain
Cipla completes transfer of Generics Business Undertaking
Subscribe To Our Newsletter & Stay Updated
